FDA rethinking block on compounding of Lilly's obesity drug
The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to investigate whether shortages of the drug, which is sold by Lilly as Mounjaro for diabetes and Zepbound for obesity, have actually been resolved as reported earlier this month.